Cargando…

Association between radiotherapy protocol variations and outcome in the CONVERT trial

BACKGROUND: Radiotherapy quality assurance (QA) is integral to radiotherapy delivery. Here we report comprehensive contouring, dosimetry, and treatment delivery QA, describe protocol compliance, and detail the impact of protocol variations on acute grade ≥3 toxicity, progression free survival (PFS),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mir, Romaana, Groom, Nicki, Mistry, Hitesh B., Wilson, Elena, Faivre-Finn, Corinne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791806/ https://www.ncbi.nlm.nih.gov/pubmed/36578530 http://dx.doi.org/10.1016/j.ctro.2022.100560

Ejemplares similares

Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status
por: Faivre-Finn, Corinne, et al.
Publicado: (2016)

Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial
por: Christodoulou, Marianna, et al.
Publicado: (2019)

(18)F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial
por: Manoharan, Prakash, et al.
Publicado: (2019)

Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial
por: Salem, Ahmed, et al.
Publicado: (2018)

Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study
por: Haslett, Kate, et al.
Publicado: (2016)

Automatic evaluation of contours in radiotherapy planning utilising conformity indices and machine learning
por: Terparia, Samsara, et al.
Publicado: (2020)

Radiotherapy tumor volume for limited-stage small cell lung cancer: less is more
por: Levy, Antonin, et al.
Publicado: (2020)

Thoracic radiotherapy in small cell lung cancer—a narrative review
por: Levy, Antonin, et al.
Publicado: (2021)

Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging
por: Salem, Ahmed, et al.
Publicado: (2018)

The evolving role of radiotherapy in non-small cell lung cancer
por: Brown, Sean, et al.
Publicado: (2019)

Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer
por: Conibear, John, et al.
Publicado: (2018)

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
por: Lee, Siow Ming, et al.
Publicado: (2014)

Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial
por: Tay, R Y, et al.
Publicado: (2019)

Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study
por: Haslett, Kate, et al.
Publicado: (2021)

Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform
por: Fornacon-Wood, Isabella, et al.
Publicado: (2020)

Optimising use of 4D-CT phase information for radiomics analysis in lung cancer patients treated with stereotactic body radiotherapy
por: Davey, Angela, et al.
Publicado: (2021)

Impact of small residual setup errors after image guidance on heart dose and survival in non-small cell lung cancer treated with curative-intent radiotherapy
por: Johnson-Hart, Corinne, et al.
Publicado: (2020)

Gender equality and leadership in radiation oncology research: a plea to women to come forward
por: Faivre-Finn, Corinne
Publicado: (2023)

Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE
por: Walker, Katrina, et al.
Publicado: (2022)

Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions
por: Banfill, Kathryn, et al.
Publicado: (2021)

On the reporting and analysis of a cancer evolutionary adaptive dosing trial
por: Mistry, Hitesh B.
Publicado: (2021)

Heart dose and cardiac comorbidities influence death with a cardiac cause following hypofractionated radiotherapy for lung cancer
por: Banfill, Kathryn, et al.
Publicado: (2022)

Predicting cancer relapse following lung stereotactic radiotherapy: an external validation study using real-world evidence
por: Davey, Angela, et al.
Publicado: (2023)

On the relationship between tumour growth rate and survival in non-small cell lung cancer
por: Mistry, Hitesh B.
Publicado: (2017)

Impact of Introducing Intensity Modulated Radiotherapy on Curative Intent Radiotherapy and Survival for Lung Cancer
por: Fornacon-Wood, Isabella, et al.
Publicado: (2022)

Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice
por: Haslett, Kate, et al.
Publicado: (2018)

Role of Real-World Data in Assessing Cardiac Toxicity After Lung Cancer Radiotherapy
por: Abravan, Azadeh, et al.
Publicado: (2022)

The CERN control protocol for power converters
por: Barnett, I, et al.
Publicado: (1993)

The CERN control protocol for power converters
por: Barnett, I, et al.
Publicado: (1992)

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
por: Mulvenna, Paula, et al.
Publicado: (2016)

Learning and Investigation of the Role of Angiotensin-Converting Enzyme in Radiotherapy for Nasopharyngeal Carcinoma
por: Ding, Yanan, et al.
Publicado: (2023)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
por: Haslett, K., et al.
Publicado: (2021)

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
por: Faivre-Finn, Corinne, et al.
Publicado: (2017)

Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?
por: Lewis, T.S., et al.
Publicado: (2020)

Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway
por: Hodson, David, et al.
Publicado: (2023)

Complex versus simple models: ion-channel cardiac toxicity prediction
por: Mistry, Hitesh B.
Publicado: (2018)

QSP Versus the Rest: Let the Competition Commence!
por: Mistry, Hitesh B.
Publicado: (2018)

Angiotensin Converting Enzyme Inhibitors Combined with Exercise for Hypertensive Seniors (The ACES Trial): Study Protocol of a Randomized Controlled Trial
por: Harper, Sara A., et al.
Publicado: (2020)

Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications
por: Batumalai, Vikneswary, et al.
Publicado: (2020)

The impact of baseline shifts towards the heart after image guidance on survival in lung SABR patients
por: Johnson-Hart, Corinne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s7dd6s8k2pu09sf0vll4r8g347